DnaK Therapeutics partnered with GATC Health in September 2026 to evaluate 16 potential cancer drug candidates using predictive artificial intelligence.
The collaboration aims to identify a smaller group of compounds for experimental testing as the company works toward selecting a lead development candidate, according to Drug Target Review. Choosing which drug candidates move forward is a hard hurdle during early development. Strong target activity alone does not guarantee further progression when doubts persist about safety, selectivity, and therapeutic outcomes.
The programme focuses on bacterial DnaK, a molecular chaperone protein implicated in chemotherapy resistance. DnaK Therapeutics is designing targeted small-molecule inhibitors to disrupt this pathway and improve patient response to current cancer therapies.
GATC Health uses its Operon AI system to evaluate the compounds and produce Derisq reports detailing their expected efficacy, safety profiles, and prospective off-target consequences. Dr Rahul Gupta, President of GATC Health, explained why candidate selection requires more than identifying the compound with the strongest target activity.
DnaK is a bacterial heat shock protein belonging to the Hsp70 family of molecular chaperones. It helps correct protein folding and allows bacteria to survive under stressful conditions. Studies indicate that bacterial DnaK also disrupts normal human cellular functions, such as pathways responsible for DNA repair and tumor suppression. This creates a selectivity challenge.
Compounds designed to inhibit bacterial DnaK can also interact with human Hsp70 family members. “It creates a more complex selectivity and systems biology problem. The target originates from bacteria, but its effects occur within a human tumour microenvironment, so we have to think about the bacterial target, the host biology and the cancer biology together rather than in isolation.” Dr Rahul Gupta, President of GATC Health, said.
Experimental support for bacterial DnaK as a viable therapeutic target appears in a 2024 paper featured within the Journal of Translational Medicine by Mongodin, Jonathan H.
When investigators exposed human gastric and colorectal cancer cell lines to recombinant bacterial DnaK, the proteins diminished the tumor-fighting efficacy of cisplatin and 5-fluorouracil across most testing conditions. The team investigated human primary cancer sequencing datasets from The Cancer Genome Atlas. Treatment with the DnaK-binding peptide ARV-1502 restored chemotherapy activity in the experimental models, according to Drug Target Review.
GATC Health, based in Irvine, California, built the Operon platform that drives this collaboration. The company states its system can deliver three to five optimized compounds ready for preclinical testing in four to six months, compared with 18 to 24 months for AI-assisted discovery and 36 to 48 months for traditional methods. The platform also underwent a blind validation test via the University of California, Irvine.
These results are in the preclinical phase. Laboratory testing must prove the potency and selectivity of the 16 compounds from DnaK Therapeutics. Assessing the value of predictive AI depends on how accurately digital simulations match real-world laboratory data.
GATC Health said that its system underwent a blind validation test via the University of California, Irvine. Testing will determine if the forecasted variances among the compounds hold true in the lab, and DnaK Therapeutics will narrow its selection to high-priority candidates for wet-lab testing.
Earlier coverage: Defence-in-Depth Framework Proposed for Securing AI-Driven Biological Sequence Design
- Kris Jenner Reveals ‘Mona Lisa’ Vaginal Laser Treatments for ‘Perfect and Cute’ Results
- Prenatal Caffeine Disrupts Sertoli Cells via GR/P300/miR-199a-5p/WT1 Pathway
- AI to Prioritise 16 Cancer Drug Candidates Targeting Bacterial DnaK (world-today-news.com)
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)